Amylin, Alkermes and Lilly announce exenatide tQT study meets pre-specified primary endpoint

07/08/11 Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

+

-

 

Exenatide tQT Study Showed No Prolongation Of QT Interval

07/11/11 Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced results from a thorough QT (tQT) study that assessed the potential of exenatide to increase the QT interval across a wide range of plasma concentrations.

+

-

 

The Zacks Analyst Blog Highlights: Alkermes, Amylin Pharmaceuticals, Eli Lilly and Company, Liberty Property Trust and ...

07/13/11 The Zacks Analyst Blog Highlights: Alkermes, Amylin Pharmaceuticals, Eli Lilly and Company, Liberty Property Trust and Duke Realty

+

-